Arcturus Therapeutics Holdings Inc.
ARCT
$12.47
-$0.17-1.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 143.68M | 152.31M | 160.40M | 163.87M | 124.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 143.68M | 152.31M | 160.40M | 163.87M | 124.53M |
| Cost of Revenue | 122.19M | 140.87M | 133.71M | 145.65M | 145.01M |
| Gross Profit | 21.50M | 11.45M | 26.69M | 18.22M | -20.49M |
| SG&A Expenses | 49.29M | 52.82M | 52.95M | 53.05M | 53.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.76M | 247.98M | 240.95M | 252.99M | 247.90M |
| Operating Income | -82.08M | -95.67M | -80.55M | -89.12M | -123.37M |
| Income Before Tax | -68.57M | -80.94M | -62.38M | -70.59M | -105.20M |
| Income Tax Expenses | -371.00K | -3.00K | 263.00K | 1.37M | 2.10M |
| Earnings from Continuing Operations | -68.20 | -80.94 | -62.64 | -71.96 | -107.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.20M | -80.94M | -62.64M | -71.96M | -107.30M |
| EBIT | -82.08M | -95.67M | -80.55M | -89.12M | -123.37M |
| EBITDA | -78.64M | -92.13M | -77.01M | -85.67M | -120.09M |
| EPS Basic | -2.52 | -3.00 | -2.33 | -2.69 | -4.03 |
| Normalized Basic EPS | -1.59 | -1.88 | -1.45 | -1.65 | -2.47 |
| EPS Diluted | -2.53 | -3.00 | -2.33 | -2.69 | -4.03 |
| Normalized Diluted EPS | -1.59 | -1.88 | -1.45 | -1.65 | -2.47 |
| Average Basic Shares Outstanding | 108.14M | 107.91M | 107.54M | 107.05M | 106.64M |
| Average Diluted Shares Outstanding | 108.14M | 107.91M | 107.54M | 107.05M | 106.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |